Adagio Medical Holdings (ADGM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Nov, 2026Executive summary
Special meeting scheduled for December 2026 as a virtual webcast; the Board recommends voting FOR both proposals.
A 1-for-30 reverse split took effect November 6, 2026, with split-adjusted trading beginning November 9.
Voting matters and shareholder proposals
Proposal 1 seeks authority for one or more reverse splits, up to an aggregate 1-for-1,000, to support Nasdaq listing compliance; the Board would choose the ratio and timing.
Proposal 2 authorizes adjournment, if needed, to solicit votes for Proposal 1; both proposals require a majority of votes cast and are treated as routine matters.
Record holders as of November 16, 2026, may vote; each common share carries one vote, and voting is available by mail, phone, internet, or webcast.
Rule 14a-8 proposals for the 2027 annual meeting are due by December 31, 2026; other proposals or nominations are due February 16–March 18, 2027, subject to meeting-date changes.
Board of directors and corporate governance
If approved, the Board may implement or abandon a split within one year of approval without another stockholder vote; it will announce a selected ratio at least five business days before effectiveness.
Board considerations include Nasdaq compliance, share price and expected stability, liquidity, market conditions, economic conditions, and market capitalization.
The Board states the split is not intended as a going-private transaction or as part of an anti-takeover plan.
Latest events from Adagio Medical Holdings
- Stockholders approved board discretion for a 1-for-10 to 1-for-500 reverse split.ADGM
EGM 2026 - Reverse-split authority seeks Nasdaq compliance amid unresolved listing deficiencies.ADGM
Proxy filing - Purpose-built VT ablation system shows strong clinical results and targets a $5.8B market.ADGM
Corporate presentation - Approval sought for a reverse stock split to maintain Nasdaq listing and address compliance issues.ADGM
Proxy filing - Net loss widened to $6.7M in Q2 2026, with no revenue and cash reserves at $7.7M.ADGM
Q2 2026 - Directors and auditor ratified with no shareholder questions; results to be filed on Form 8-K.ADGM
AGM 2026 - Ultra-low temperature VT ablation tech shows strong results and targets rapid U.S. market entry.ADGM
Small Cap Growth Virtual Investor Conference - Ultra-low temperature VT ablation tech targets $5.8B market with FDA approval expected in 2026.ADGM
25th Annual Needham Virtual Healthcare Conference - Ultra-low temperature ablation achieved 2.4% safety and 98% acute effectiveness in VT therapy.ADGM
KOL event